Background
Introduction to Pancreatic Cancer
Cancer is a devastating disease, and of the 18 million diagnosed globally in 2018, approximately 500,000 cases were pancreatic [ 1 ]. Furthermore, pancreatic cancer (PC), in all forms, has the lowest survival rate of any cancer type; with less than 1% overall 10-year survival, and 3% overall 5-year survival based on statistics of patients from England and Wales [ 2 ]. Although significant progress has been made in the development of novel cancer therapies, PC survival rates have failed to improve in the last 40 years [ 2 ]. A fundamental reason for this is that PC typically presents as an advanced disease with extensive metastatic deposits that arise in the liver [ 3 ]. Additionally, surgeons are often reluctant to conduct resections on local tumours due to growth around vital arteries and para-aortal metastases [ 4 , 5 ].
The evolution of genetic mutations required for metastasis can take over a decade to come into fruition from the initial primary non-metastatic cell within the pancreas [ 3 ]. This means that if the disease is detected within the first couple of years of tumorigenesis, there is a significantly improved chance of disease control with effective treatment [ 6 ]. Abdominal pain and abnormal digestive patterns have been reported to be recurring in 70% patients with PC diagnosis, which in later stages become more apparent with specific patterns identified [ 7 ].
Diabetes mellitus (DM) is unsurprisingly found in two thirds of PC patients. Studies consistently show an increase in the risk of PC development with type 2 DM [ 8 ]. Furthermore, in a recent study by Wang et al. [ 9 ], DM was linked with increased metastasis in PC patients. These findings were linked to an increased inflammatory response accompanied by high glucose levels promoting PC progression [ 9 ]. Nonetheless, the pancreatic tumour itself can be diabetogenic resulting in dysfunctional β-cells, required for insulin production [ 10 ]. This explains the association of PC with 10% of new-onset diabetes [ 11 ], as well as highlighting newly developed DM as a possible PC symptom.
Taken together, these facts indicate that PC is still a challenge in terms of diagnosis, treatment and prognostic outlook. This review therefore will explore the molecular changes which can occur in PC development and progression, and how (microRNA) miRNA can play a role in terms of, disease screening, prognoses and new therapeutic options.
Main text
Molecular changes during Pancreatic carcinogenesis
The development of PC is a multistage process that involves alterations in well-characterised genes [ 12 ]. One of the most commonly mutated oncogenes is the Kirsten Rat Sarcoma (K-RAS) gene, detected in 90% of PC cases [ 11 ].
Typical PC tumour suppressor mutations can be found in cyclin-dependent kinase (CDKN2A), tumour protein 53 (TP53), mothers against decapentaplegic homolog 3 (SMAD3), and breast cancer A2 (BRCA2) [ 13 ]. These genetic mutations result in histological and morphological abnormalities within the ductal cells of the pancreas, forming papillary-like structures. These papillary lesions then transform into more complicated preneoplastic lesions known as pancreatic intraepithelial neoplasia (PanIN) [ 14 ]. The formation and development of PanINs occur in a stepwise linear manner that is concurrent with the aforementioned genetic mutations. As a result, more complicated structures develop, progressing to the invasive (carcinoma) tumour cells (Fig. 1 ). Thus, PanINs are classified based upon cellular morphology, as PanIN-1A, −1B, − 2 or − 3. PanIN-1A and PanIN-1B are more elongated compared to the normal ductal cells and cells with flat structures fall under the PanIN-1A subgroup. Both A and B subgroups are linked by the early mutation of the K-RAS oncogene. With the inactivation mutation of CDKN2A, the lesions progress and acquire moderate nuclear abnormality, forming PanIN-2. Ultimately, nuclear atypia ensues with the budding of cells into the ductal-like structure in the late lesions known as PanIN-3. These late lesions arise as a result of inhibitory mutations of p-16 and SMAD-4 and are also dubbed as in situ carcinoma [ 15 ]. PanINs can also be divided into low-grade or high-grade, with a high rate of occurrence of low-grade in the early stages of PC and excessive tumour invasion happening in the later stages [ 16 ]. Fig. 1 Schematic representation of the development of PC and associated genes in each stage. The precursor lesions (PanINs) give rise to PC in a multistage process that is mediated through consecutive genetic mutations starting with early K-RAS oncogenic activation and ending in multiple tumour suppressors silencing. Source: MS Powerpoint
Oncogene activation
K-RAS is a member of the Ras family, a guanosine triphosphate (GTP) family of bound proteins. Active Ras proteins bind to GTP and are responsible for proliferation, cell survival and cytoskeletal remodelling through the regulation of several downstream modulators. The activity of Ras is then terminated through the hydrolysis of GTP into guanosine diphosphate (GDP), mediated by GTPase activating protein (GAP) [ 17 ].
Mutations arise in the K-RAS oncogene in glycine 12 (G12), glycine (G13), or glutamine (Q61L) resulting in sustained K-RAS activity through maintaining the GTP-bound active form of the protein [ 18 ]. This results in persistent activation of the downstream signalling pathways, which will be translated in a typical cancerous cell phenotype including aberrant proliferation, microenvironment alterations, apoptosis suppression and cell survival.
To study the impact of mutated K-RAS on tumour progression, Collins et al. [ 19 ] engineered two mouse models to have reversibly inducible K-RAS mutation that is tissue-specific. The two models are iK-Ras* and iK-Ras-p53 +/− , in which the latter has an extra inactivation mutation of one allele of the p53 gene. These mouse models are believed to develop pancreatic lesions in a manner mimicking human disease, with PanINs developed within three weeks of K-RAS mutation induction in the iK-Ras* model. This model was used to demonstrate the key role of K-RAS in the initiation of the tumours. On the other hand, inactivation of K-RAS mutation in the iK-Ras-p53 +/− model resulted in tumour regression. The same response was noted by other authors using the iK-Ras mouse model [ 20 ]. They have recorded rapid tumour and stromal deterioration upon turning the K-RAS mutation off, with 50% reduction in tumour mass after 48–72 h of K-RAS genetic inhibition [ 20 ]. These findings elucidate the importance of K-RAS in maintaining carcinogenesis irrespective of any additional mutations, in a phenomenon known as “ K-RAS addiction ” [ 21 ]. Oncogene addiction materialises when a cancer requires the sustained activation of a specific oncogene, even after the incorporation of additional genetic mutations through advanced stages [ 22 ]. This phenomenon doesn’t repudiate the importance of additional mutations on tumour suppressor genes in the progression of tumours, as the tumours formed in the absence of other tumour suppressor mutations were stable with infrequent invasiveness [ 20 , 23 ]. This does indicate that the K-RAS gene could be a potent therapeutic intervention in pancreatic cancer.
The two main downstream pathways of activated K-RAS include mitogen-activated protein kinase (MAPK) [ 24 ] and phosphoinositide-3-kinase (PI3K) [ 25 ], which have significant roles in promoting cell survival and proliferation. MAPK is a superfamily of protein kinases, including subfamilies that are identified and characterised in mammalian cells: extracellular signal-regulated kinases (ERK1/ERK2), the c-Jun N-H2 terminal kinases/stress-activated protein kinase (JNK/SAPK), and the P38 enzymes. Activation of the MAPK pathways is associated with poor prognosis in PC patients through the activation of several downstream pathways. Of these pathways, ERK1/2 [ 26 ] and P38 [ 27 ] are critical downstream modulators; however, the role of the P38 pathway is contradictory. As shown by Handa-Luca et al. who studied 99 surgically resected PC, increased cytoplasmic levels of P38 and ERK1/2 were linked with high recurrence after surgical resection of PC, and lower overall survival rates of 7 months compared to 35 months for patients showing low cytoplasmic levels [ 28 ]. Interestingly, through the analysis of 36 rapid biopsies from patients, increased levels of P38 were linked with good prognosis. This was evident as the postoperative survival was noted, with a median survival rate of 27.9 months in patients showing high levels of P38 compared to 14.7 months in those with low P38 expression [ 29 ]. The samples from this study were taken from patients presenting with all types of PC, whereas the study conducted by Handa-Luca et al. contained only pancreatic ductal adenocarcinomas patient samples. This highlights the diversity in PC and how molecules can have multiple roles.
The progressive role of inflammatory stress accompanied with the tumour microenvironment is believed to be activated through the P38 pathway [ 30 ]. Huang et al. recorded increased proliferation and invasion of a PC cell line, PANC-1, upon targeting the β-adrenergic receptors with the stress hormone, norepinephrine (NE), which was accompanied by elevated levels of the active phosphorylated P38 [ 30 ]. Yet, Ding et al. demonstrated that upon the inhibition of P38 MAPK pathway, ERK1/2 phosphorylation increased, which translated to the enhancement of PANC-1 proliferation [ 31 ].
These findings indicate that the P38-MAPK pathway has a controversial role in the development of pancreatic cancer. This contradiction may be explained by the availability of four different P38 paralogues: P38α, P38β, P38γ and P38δ (reviewed in [ 32 ]) which should be further interrogated.
Tumour suppressor gene mutations
The CDKN2A gene encoding p16 is a tumour suppressor commonly inactivated in pancreatic cancer (90% of the cases [ 33 ]). The CDKN2A gene encodes two families of tumour suppressor proteins. Out of these families, inhibitors of the CDK4 (INK4) family is denoted mainly by p16 and p19 which are located on the same locus. However, these proteins are not considered to be isoforms of each other since they are being translated from two separate messenger RNAs (mRNA) produced by CDKN2A [ 34 ]. The most abundant inactivation mutation is believed to happen uniquely on p16. Inactivation of p16 can occur via homozygous deletion, intragenic mutations or epigenetic silencing [ 33 , 34 ], which results in cell cycle disruption through the G1/S checkpoint inhibition. This disruption will result in uncontrolled transcriptional activation which will contribute to a positive feedback loop, leading to increased cell division and proliferation [ 35 ].
Another mutated tumour suppressor gene is TP53 encoding for p53, a transcription factor that is activated by cellular stress [ 36 ]. DNA damage, radiation, aberrant growth signals and some chemotherapeutic agents will cause cellular stress, thus activating the p53 pathway [ 37 ]. P53 activation results in cell division, inhibition, or in the case of extremely damaged cells, death through apoptosis [ 36 ]. The p53 mutation was recorded in 70% of PC, which mainly presents as a loss of function [ 38 ]. However, these mutations can also provide oncogenic function, as p53 silencing has been shown to increase the expression of platelet-derived growth factor receptor b (PDGFRb) which correlates directly with invasiveness and metastasis [ 39 , 40 ].
Both tumour suppressor proteins p16 and p53 bind and inactivate CDK2 and 4 which impacts the cell cycle by preventing transition from G1 to S phase [ 41 , 42 ]. Any inactivation of these proteins will result in cell cycle progression despite the G1/S checkpoint status ensuring continuous proliferation [ 43 ].
Another tumour suppressor gene that is commonly deregulated in PC is the pancreatic carcinoma 4 gene (DPC4, also known as SMAD4), which is upregulated in 55% of PC [ 41 ]. Loss of SMAD4 facilitates a selective growth advantage, through the regulation of the transforming growth factor-β (TGF-β) signalling pathway [ 42 ]. Upon activation of the TGF-β pathway, an intracellular cascade takes place through activation of the cell surface serine-threonine kinase receptor type II (TβRII) which will cause activation of the type I receptor through phosphorylation of the glycine- and serine-rich sequence (GS) domain located on the N-terminal of the type I receptor [ 42 ]. Receptor-activated SMADs, called R-SMADs, form trimeric complexes composed of two R-SMADs and an essential co-SMAD which is the SMAD4. These tri-complexes, translocate to the nucleus and target DNA to regulate specific genes that have anti-mitogenic and pro-apoptotic effects [ 41 , 43 ]. The importance of SMAD4 in all TGF-β pathways as an essential co-factor explains the cardinal effect of SMAD4 mutations on modulating most genetic responses to the TGF-β superfamily.
Ultimately, cellular anaplasia and relapses, lymphatic invasion, postoperative recurrence, tumour size and metastasis to lymph nodes status have all been linked to mutations in p53, p16, and SMAD4 [ 44 ]. Thus, all of these genetic mutations offer great potential for gene therapy interventions. The utilisation of miRNA for the targeting of these mutations presents an opportunity to regulate multiple pathways with a single therapeutic [ 45 ].
miRNAs
MicroRNAs form a subfamily of non-coding RNAs which regulate gene expression via mRNA degradation or translatory inhibition [ 46 ]. Approximately 50% of miRNAs are encoded on non-protein-coding regions and are independently transcribed. The remaining miRNAs are encoded on introns of protein-coding transcripts. In this case, miRNAs are referred to as intergenic miRNA and will be transcribed with host genes and processed separately to produce the mature independent miRNA [ 47 ]. The biogenesis of miRNAs is summarised in Fig. 2 . Fig. 2 The process of miRNA biogenesis and role in post-transcriptional suppression. The biogenesis of miRNAs commences in the nucleus where the RNA polymerase II transcribes the genetic sequence encoding the miRNA to produce a primary miRNA hairpin (pri-miRNA) which is capped, polyadenylated and has a stem-loop structure. Further processing by the ribonuclease DROSHA enzyme occurs in the nucleus before the resultant 70 to 100 nt long pre-miRNA hairpin is transported to the cytoplasm via the Exportin5 protein (XPO5). Once the double stranded pre-miRNA is in the cytoplasm, RNAse DICER cleaves the molecule into two single strands, with a leading functional strand, and a passenger strand -often referred to as (*)- which will be degraded. The Ago proteins bind to the leading single stranded miRNA to form the RISC. The RISC is considered to be the functional unit in this process which facilitates the binding of miRNA into the targeted mRNA resulting in either translation repression or target degradation. Source: MS Powerpoint
Activated miRNA is incorporated within the RNA-induced silencing complex (RISC), and this multipart will bind to the target mRNA, typically on a conserved site called the seed region. This region is included within the 3′ untranslated region (3’UTR) between nucleotide 2–8, and functions as a target recognition site as the binding between the two strands has 100% complementarity [ 48 ]. Conserved seed matches are linked with more knockout potency as a single nucleotide change alters the possible targets by more than 50% [ 49 ].
The cornerstone of miRNA binding is based on 3 rules: perfect or near-perfect complementary binding in the seed region, central region mismatches or “bulges” and the reasonable complementarity throughout the full sequence of the miRNA with the target. It is important to mention that complementarity through the two sequences is particularly significant in the case of suboptimal binding in the seed region. While the full sequence of the miRNA has possible base mismatches, these mismatches do not affect the functionality of the complex. In fact, it gives the miRNA more extensive mRNA target possibilities [ 48 ]. The importance of complementary binding in the seed region is explained by the fact that it is the cornerstone in target recognition. Furthermore, the bulges facilitate the binding and functionality of the Ago protein, an essential component of the RISC required for the assembly and guidance to target mRNAs [ 50 ]. Lastly, the manner of complementary binding throughout the miRNA and the target mRNA sequence will determine the inhibitory mechanism of the translation process. If the binding occurs in a perfect complementary fashion throughout the whole sequence, complete degradation of the target mRNA will take place [ 51 ]. On the other hand, if few base pair mismatches were present during the binding process, the translation blockade will ensue through destabilisation of the target mRNA by non-splicing mechanisms. These mechanisms include decapping or deadenylation which represents the most abundant mechanism of silencing [ 48 , 52 ].
Exosomes are extracellular vesicles which are endosomal in basis and typically range in size between 40 and 100 nm and function to secrete and carry biological materials between cells [ 53 ]. MiRNA can also be secreted from cells within exosomes, and these ‘exomiRNAs’ have exhibited extensive evidence of influencing cancer initiation and development. For example, exosomal miRNA-301a was found to trigger the M2 polarisation of macrophages when derived from hypoxic pancreatic cancer cells which was attributed to the activation of the PTEN/PI3Kγ pathway [ 54 ]. Interestingly, studies have shown that exomiRNAs have the potential to be novel biomarkers collected from blood serum. Studies conducted by Pang et al. showed that pancreatic cancer cells produce and secrete miRNA-155 within exosomes, with the function of activating fibroblasts [ 55 ]. Furthermore, exosomes are non-immunogenic and protect biological cargo thus make for excellent gene therapy systems. However, major hurdles of getting exosomes into the clinic include the efficient loading of miRNA into exosomes, with influencing factors including solubility and charge. Furthermore, the pathways on which any therapeutic miRNA functions would need to be extensively defined, to avoid undesirable off-target effects [ 56 ].
miRNA in Pancreatic Cancer
miRNAs play a major role in carcinogenesis, falling into two categories: tumour suppressor miRNAs, and oncogenic miRNAs (also termed oncomiRs) [ 57 ]. The classification is dependent on the role of the target mRNAs in the tumour initiation process. Normally, oncogenes and tumour suppressor genes are regulated at an optimal activation/inhibition equilibrium. If downregulation of a specific miRNA increases the activity of a corresponding oncogene, this is identified as a tumour suppressor miRNA. On the other hand, if upregulation of an oncomiR takes place, it will result in a continuous inhibition of the target tumour suppressor gene. This uncontrolled inhibition will result in the loss of controlling specific tumour formation pathways. Deregulation in any of the miRNA types will contribute to the development of tumours [ 58 ].
Patterns of miRNA expression vary markedly between cancer types; thus, the use of miRNA expression profiles could be used as a promising non-invasive diagnostic markers. Furthermore, miRNA profiling should have superiority over using mRNA profiles as they can represent many more reliable targets [ 59 ]. Identification of a small number of miRNA has been shown to be more reliable than the data from 16,000 mRNAs with a more robust hierarchical clustering [ 59 ]. In pancreatic cancer, different patterns have been found in miRNA expression profiles, which have contributed to the development of a miRNANome between the normal and cancerous pancreas [ 60 ]. Determination of these miRNA expression profiles has been made possible through different gene profiling methods, mainly microarrays, RNA-sequencing, and RT-PCR analysis of specimens [ 61 ]. Due to the stability of miRNA in circulation, blood screening could be employed as an approach to detect specific miRNA which have been linked with stage, survival rate or aggressiveness of the disease [ 62 – 64 ].
Variations in the results observed among different studies are generally thought to be caused by ethnicity and regional differences [ 65 ]. Another important factor is the sampling procedure, as fine needle aspiration (FNA) results in enriched samples with a specific tumour component, disregarding other cell types during the microdissection process. This observation was illustrated by the molecular differences obtained from bulk samples compared to fine needle aspirations[ 66 ]. Comparing expression patterns among different samples could also allude to the abundance of miRNAs among different cell types that are naturally occurring in the pancreas, as well as the tumour microenvironment. For example, miRNA-375 was suggested to be linked with the islet cells [ 67 ], as the expression was high in normal pancreatic tissues compared to the cancerous and inflammatory tissues with a complete absence in representative cell lines [ 60 ].
miRNA samples can also be obtained via non-invasive routes from, peripheral blood, saliva, urine or faeces [ 68 ]. Abue et al. conducted a study to analyse the potential of miRNA-483-3p and miRNA-21 as biomarkers of pancreatic ductal adenocarcinoma from blood plasma. These plasma samples were obtained from 32 patients presenting with pancreatic ductal adenocarcinoma, 12 patients with intraductal papillary mucinous neoplasm, and 30 healthy control individuals. The levels of these miRNA were evaluated using qRT-PCR, compared between groups and the expression of each was linked clinically. The plasma expression of both miRNA-483-3p and miRNA-21 was found to be significantly higher in pancreatic ductal adenocarcinoma compared to healthy controls ( p < 0.01). The plasma expression of miRNA-483-3p was significantly higher compared to intraductal papillary mucinous neoplasm ( p < 0.05), and the expression of miRNA-21 was linked to advanced stage disease ( p < 0.05) with metastases in the lymph nodes and liver ( p < 0.01). Indeed, miRNA expression correlated with an overall lessened survival in those patients with pancreatic ductal adenocarcinoma ( p < 0.01) [ 69 ].
miRNAs as biomarkers
Identification of early biomarkers is essential in cases where PC surgical resection is the only curative treatment. Surgery is only feasible in 15–20% of patients who have been diagnosed with early stages of PC [ 70 , 11 ]. However, the postoperative complications associated with this surgery are frequent and cases such as chronic pancreatitis or pancreatic tuberculosis are usually hard to differentiate from cancer cases [ 71 ]. To date, the serum carbohydrate antigen 19–9 (CA 19–9) has been employed as a marker for assessing clinical treatment efficacy in pancreatic cancer [ 72 ]. Limitations associated with CA 19–9 include ineffectiveness, low sensitivity and low specificity, yet it is still the only FDA approved marker in PC. Other antigens such as CEA, and CA125 were completely ineffective as early markers, but some oncologists still use them as markers of therapy responsiveness [ 73 ]. Therefore, the PC diagnostic biomarker need could be met by utilising identified miRNAs as an early screening test [ 74 ]. Advantages of using miRNAs include stability in serum, ease of non-invasive detection in circulation and a convenient screening method [ 75 ].
Lee et al. used pancreatic cancer, paired benign pancreatic tissue, normal pancreas, and pancreatitis tissues along with nine cell lines to compare miRNA expression profiles [90]. This was achieved through employment of real-time PCR profiling of > 200 miRNA precursors. The diversity of sample types used gives the study a broader spectrum of comparison and a chance of detecting the premalignant changes that occur through the conversion step from benign abnormalities to malignant tumours. Among the top aberrantly expressed miRNAs (Fold change, P -value) in cancer samples, miRNA-424 (56.3, 3.62E-08), miRNA-100 (36.9, 4.40E-06), miRNA-301 (34.2, 1.11E-05), miRNA-212 (22.2, 2.00E-04) and miRNA-125b-1 (23.2, 1.00E-04) were overexpressed, whereas miRNA- 345 (− 14.5, 1.44E-15), miRNA-142-P (15.4, 3.63E-07), and miRNA-139 (− 7.91, 6.79E-11) were all downregulated, relative to normal pancreatic samples. Additionally, miRNA-221, miRNA-376a, and miRNA-301 were found to be localised within the tumour cells rather than other cells in the stroma [ 76 ].
MiRNA-155 and miRNA-21 were also found to have elevated expression in the precursor lesions, linking them with histological progression features, with a specificity of miRNA-155 as a biomarker in pancreatic juices [ 77 ]. The top five upregulated miRNA included miRNA-21, miRNA-196a, miRNA-27a, miRNA-146a, and miRNA-200a as listed by Hong and Park [ 78 ] following fine needle aspiration (FNA). In comparison, the most downregulated miRNAs included miRNA-96, miRNA-217, miRNA-141, miRNA-20a, and miRNA-29c [ 78 ]. Other upregulated candidates were demonstrated via qRT-PCR by Zhang et al., and include miRNA-196a, miRNA-190, miRNA-186, miRNA-221, miRNA-222, miRNA-200b, miRNA-15b, and miRNA-95, [ 79 ]. Further evidence also showed that miRNA-21, miRNA-26b, miRNA-194, miRNA-200b, miRNA-200c, miRNA-320, miRNA-374 and miRNA-429 were upregulated in PC cell lines compared to normal pancreas cell lines [ 80 ].
Early stage K-RAS mutations, observed in PanIN lesions, can directly affect the levels of specific miRNAs as shown by the Cordelier group [ 67 ]. Upregulation of miRNA-205, miRNA-200, and miRNA-21 was detected in early adenocarcinoma lesions, through use of a KRAS(G12D) mouse model where miRNA production could be measured in pathological and nonpathologic ducts. The level of increased miRNA-21 expression was also proportional to the degree of morphological changes within the lesions [ 81 ], as quantified using qRT-PCR of PanIN samples using U6 as a housekeeper gene. The mechanism of action of miRNA-21 is summarised in Fig. 3 . Upregulated miRNA-372, miRNA-146a, miRNA-204, miRNA-10a, and miRNA-10b were also detected in PC cell lines (CAPAN-1 and CFPAC1) compared to human normal pancreatic ductal epithelial cells, with more than 10-fold changes in the latter levels [ 82 ] observed using qRT-PCR. Fig. 3 Schematic representation of mechanism of miR21 in PC development. miRNA-21 has previously been shown to target the expression of PTEN and PDCD4. Through inhibition of PTEN via miRNA-21, cell survival pathways are activated. With Akt pathway functionality heightened, the inhibition of BAD increases, which is a pro-apoptotic pathway, thus leading to a reduction in apoptosis. PTEN also inhibits angiogenesis within the VEGF pathway, thus miRNA-21 can enhance the establishment of new vasculature. Source: MS Powerpoint
A further study [ 60 ] showed distinct expression levels in normal pancreatic tissues. Candidate miRNAs: miRNA-141, miRNA-148a, miRNA-200a, miRNA-200b, miRNA-200c, miRNA-216, miRNA-217, and miRNA-375 exhibited high expression levels in the normal pancreatic tissue compared with 33 other human tissues analysed in the same array. Alternatively, there were low expression levels with miRNA-133a, miRNA-143, miRNA-145, and miRNA-150 in cancerous tissue[ 60 ]. MiRNA-216 and miRNA-217 were found to have extensive infiltration in normal pancreatic tissues, and neglible levels in both cancerous tissue and pancreatic cell lines. The unique expression of these two miRNAs in normal pancreatic tissue samples compared to diseased tissues and cell lines renders a specificity for the pancreatic abundance. A global study also showed that both miRNA-216 and miRNA-217 were absent from 33 different human tissues [ 60 ]. MiRNA− 93, miRNA-196a, miRNA-196b, miRNA-203, miRNA-205, miRNA-210, miRNA− 221, miRNA-222 and miRNA-224 were upregulated only in cancerous tissues and cell lines. This observation is linked with a potential role in the neoplastic process. Special interest should be directed towards miRNA-196a and miRNA-196b as complete absence was observed in the normal and pancreatitis tissues. This gives a potential selectivity to pancreatic cancer as detailed in Table 1 [ 60 ]. Table 1 miRNAs as biomarkers in pancreatic cancer (“= high mainly in early lesions) miRNA Analysis Technique Normal Pancreatic Tissues Pancreatitis PC Cell lines Reference -20a, −29c 96, − 141, Microarray High N/A Low N/A [ 78 ] -10a, −10b, − 204, − 372, Microarray Low N/A High N/A [ 82 ] -93, −133a, − 203, − 205, − 210, − 224 Microarray Low N/A High High [ 60 ] -27a Microarray Low N/A High N/A [ 78 ] -221, −222 Microarray, qRT-PCR Low N/A High High [ 60 , 79 ] -216, −217 Microarray Very high N/A Very low Very low [ 60 , 78 ] -200a Microarray, TaqMan low density array, qRT-PCR Low N/A High N/A [ 78 , 81 ] Microarray High Low [ 60 ] -196a Microarray, qRT-PCR Absent Absent High High [ 60 , 78 , 79 ] -15b, −95, −186, −190, −200b qRT-PCR Low N/A High N/A [ 79 ] -146a Microarray Low N/A High N/A [ 78 , 82 ] −143, −145, −150 Microarray Low High High Absent [ 60 ] −141, −148a, −200b, −200c, −375 Microarray, TaqMan low density array, qRT-PCR Low N/A N/A High [ 80 ] −139, −142, −345 qRT-PCR Low N/A Low N/a [ 76 ] −100, −125b-1, −212, −301, −424 qRT-PCR Low N/A High N/a [ 76 ] −21 Microarray, TaqMan low density array, qRT-PCR Low N/A High “ High [ 77 , 78 , 80 , 81 ] −155 qRT-PCR Low N/A High “ N/A [ 77 ] −205 qRT-PCR Low N/A High “ N/A [ 81 ] −375 Microarray High Low Low Absent [ 60 ]
Table 1
miRNAs as biomarkers in pancreatic cancer (“= high mainly in early lesions)
| miRNA | Analysis Technique | Normal Pancreatic Tissues | Pancreatitis | PC | Cell lines | Reference |
| -20a, −29c 96, − 141, | Microarray | High | N/A | Low | N/A | [ 78 ] |
| -10a, −10b, − 204, − 372, | Microarray | Low | N/A | High | N/A | [ 82 ] |
| -93, −133a, − 203, − 205, − 210, − 224 | Microarray | Low | N/A | High | High | [ 60 ] |
| -27a | Microarray | Low | N/A | High | N/A | [ 78 ] |
| -221, −222 | Microarray, qRT-PCR | Low | N/A | High | High | [ 60 , 79 ] |
| -216, −217 | Microarray | Very high | N/A | Very low | Very low | [ 60 , 78 ] |
| -200a | Microarray, TaqMan low density array, qRT-PCR | Low | N/A | High | N/A | [ 78 , 81 ] |
| Microarray | High | Low | [ 60 ] | |||
| -196a | Microarray, qRT-PCR | Absent | Absent | High | High | [ 60 , 78 , 79 ] |
| -15b, −95, −186, −190, −200b | qRT-PCR | Low | N/A | High | N/A | [ 79 ] |
| -146a | Microarray | Low | N/A | High | N/A | [ 78 , 82 ] |
| −143, −145, −150 | Microarray | Low | High | High | Absent | [ 60 ] |
| −141, −148a, −200b, −200c, −375 | Microarray, TaqMan low density array, qRT-PCR | Low | N/A | N/A | High | [ 80 ] |
| −139, −142, −345 | qRT-PCR | Low | N/A | Low | N/a | [ 76 ] |
| −100, −125b-1, −212, −301, −424 | qRT-PCR | Low | N/A | High | N/a | [ 76 ] |
| −21 | Microarray, TaqMan low density array, qRT-PCR | Low | N/A | High “ | High | [ 77 , 78 , 80 , 81 ] |
| −155 | qRT-PCR | Low | N/A | High “ | N/A | [ 77 ] |
| −205 | qRT-PCR | Low | N/A | High “ | N/A | [ 81 ] |
| −375 | Microarray | High | Low | Low | Absent | [ 60 ] |
miRNAs as prognostic factors
Profiling miRNAs among patient samples with different disease characteristics and stages gives an understanding of the prognostic role of miRNAs, many of which are listed in Table 2 . It was shown in a retrospective clinical study comprising 200 pancreatic ductal adenocarcinoma tissue samples (Department of Hepatobiliary and Pancreas Surgery of Seoul National University Hospital) that in a high-risk group (median survival time = 17.2 months) miRNA-574-5p, miRNA-1244, miRNA-4474-5p were upregulated. While miRNA-574-5p, miRNA-1244, miRNA-145-*, miRNA-328, miRNA-26b*, and miRNA-4321 showed association with overall survival (OS) and disease-free survival (DFS) [ 83 ]. Taubert and coworkers [ 84 ] have investigated the role of miRNA-155, miRNA-203, miRNA-210, miRNA-222, miRNA− 216, and miRNA-217 in overall survival. Upregulation of the first four of this group showed a correlation with poor prognosis and overall survival, while the same effect has been noticed with the downregulation of miRNA-217. In terms of miRNA-216, no effect has been detected in either up or downregulation. Tumour-related death increased 5.24-fold when the overexpression of miRNA-155, miRNA-203, miRNA-210, and miRNA-222 is combined [ 84 ]. miRNA-21 is also another indicator of poor outcome [ 85 , 86 ]. Increased expression of miRNA-196a-2 resulted in a lower survival time (median survival time = 14.3 months) compared with downregulated expression (median survival time = 26.5 months) [ 86 , 87 ]. Similar effects occurred with miRNA-219 as the median survival rate was 13.6 months in the overexpressing tumours, and 23.8 months in the tumours with downregulated miRNA-219 [ 88 ]. Table 2 miRNAs as prognostic factors and the associated targets and survival status in pancreatic cancer miRNA Expression in Pancreatic Cancer compared to normal tissue Survival Status Targets Reference -10b Upregulated Poor Survival TIP30 [ 94 , 95 ] −21 Upregulated Worse Survival PTEN, PDCD4, IL-6R,CDK6 [ 85 – 87 ] -34a Upregulated Better Survival NOTCH, BCL2, CDK6 [ 96 – 98 ] −155 Upregulated Poor Survival TP53INP [ 99 , 100 ] -let-7 Family Downregulated Poor Survival KRAS, HRAS, TRIM71 [ 101 , 102 ] −200 Family Downregulated Better Survival E-cadherin, ZEB [ 91 , 96 , 103 ] −216 Downregulated Poor Survival ROCK1 [ 104 , 105 ]
Table 2
miRNAs as prognostic factors and the associated targets and survival status in pancreatic cancer
| miRNA | Expression in Pancreatic Cancer compared to normal tissue | Survival Status | Targets | Reference |
| -10b | Upregulated | Poor Survival | TIP30 | [ 94 , 95 ] |
| −21 | Upregulated | Worse Survival | PTEN, PDCD4, IL-6R,CDK6 | [ 85 – 87 ] |
| -34a | Upregulated | Better Survival | NOTCH, BCL2, CDK6 | [ 96 – 98 ] |
| −155 | Upregulated | Poor Survival | TP53INP | [ 99 , 100 ] |
| -let-7 Family | Downregulated | Poor Survival | KRAS, HRAS, TRIM71 | [ 101 , 102 ] |
| −200 Family | Downregulated | Better Survival | E-cadherin, ZEB | [ 91 , 96 , 103 ] |
| −216 | Downregulated | Poor Survival | ROCK1 | [ 104 , 105 ] |
Furthermore, miRNAs could play a prolific role in the prediction of chemoresistance and responsiveness to different therapeutic approaches. For example, several markers indicate the degree of responsiveness, where miRNA-320c is a prognostic factor for gemcitabine clinical response prediction [ 89 ]. Moreover, post-surgery survival rates were higher in patients with increased levels of miRNA-200c (MST = 42 months, 5-year survival rate = 33.5%) than the lower miRNA-200c expressing individuals (MST = 19 months, 5-year survival rate = 11.2%). This observation correlated with low invasiveness of cells after the upregulation of miRNA-200c following in vitro experiments [ 90 ].
Irregular expression of miRNA was found in the development of a gemcitabine-resistant cell line. miRNA-200b, miRNA-200c, let-7b, let-7c, let-7d and let-7e were downregulated in gemcitabine-resistant cells [ 91 ]. Similarly, miRNA-33a is also downregulated in gemcitabine-resistant cells, and upon the restoration of normal levels, gemcitabine sensitivity was restored in the MIA-PaCa2 PC cell line [ 92 ]. Increased levels of miRNA-320c in gemcitabine-resistant cells suggests incorporation through regulation of SWI/SNF Related Matrix Associated Actin Dependent Regulator Of Chromatin Subfamily C Member 1 (SMARCC1), as benefits from the gemcitabine regimen were only found among the patients expressing SMARCC1. miRNA-205 was used in combination with gemcitabine as a chemosensitiser through decreased production of caveolin-1 and Ki-67 [ 93 ]. Orthotopic pancreatic mice were implanted with either lenti-hsamiRNA205 treated MIA PaCa-2R cells, or lenti-hsamiRNAScramble treated MIA PaCa-2R cells. Following intravenous delivery of GEM-conjugated polymeric micelles thrice weekly for two weeks at a concentration of 40 mg/kg, it was observed that in the lenti-hsamiRNA205 treated cells there was a significant reduction in tumour growth. These mice bore tumours with average volumes of 77.83 ± 21 mm, compared to mice implanted with lenti-hsamiRNAScramble treated cells, which exhibited tumours of volumes of 172.85 ± 17 mm.
Conclusions
Due to the aggressive nature of PC and the lack of biomarkers, miRNAs represent a promising tool to help in the development of prediction, managing, and treating agents to improve low survival rates. The therapeutic potential of miRNAs can be implicated after investigating downstream regulatory mechanisms observed among different molecular pathways, as some can play a tumour suppressive role and others are oncomiRNAs. The restoration of these miRNAs levels to that of healthy tissue could therefore be beneficial in maintaining the endogenous anti-tumour regulatory mechanisms.
However, large-scale clinical studies need to be explored to establish clinical relevance of the collected data. To date, one clinical trial is ongoing studying miRNA-25 as a diagnostic tool in PC ( NCT03432624 ) [ 106 ]. Variations in results among studies arise from using pancreatic specimens, which contain heterogenous cell populations. These cell types include the ductal, acinar, and islet cells, along with other inflammatory, fibroblastic components that will accompany the tumour development. Prediction of target genes of different miRNAs could be considered the major drawback of assigning miRNA in large scale applications, as the predictive algorithms give an enormous number of targets for a single miRNA. Attention should be given to the miRNA’s mechanism of action, as more innovative methods will be required to validate the predicted targets.
RNAs are gaining momentum as therapy options. MRX34, for example, is a miRNA-34 mimic encapsulated within a lipid-based vessel known as NOV40. MRX34 was utilised in a multicentre phase I clinical trial (2013) for the treatment of patients with primary liver cancer, melanoma, lymphoma, small cell lung cancer, multiple myeloma or renal cell carcinoma. By June 2016, 99 patients were recruited onto the trial with HCC, NSCLC or pancreatic cancers. Following completion of the trial, 3 patients achieved prolonged confirmed partial responses. Moreover, 14 patients presented with stable disease (median duration- 136 days) [ 107 ]. An example of an FDA approved RNAi based therapy by Alnylam Pharmaceuticals is Onpattro™ for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. Onpattro™ contains patisaran, which comprises a siRNA conjugated with a lipid complex. The drug’s mechanism of action results in binding with the TTR protein. The reduction in TTR protein levels in the liver results in a drop in amyloid deposits. The FDA approval of Onpattro™ in August 2018 was the result of a successful Phase III clinical trial dubbed APOLLO. The trial had 225 patients enrolled, 148 of which received Onpattro™ once every three weeks (0.3 mg/ kg body weight), while the remaining patients received a placebo drug. Patients receiving Onpattro™ displayed improvements, with 51% of patients exhibiting an improved quality of life (measured using the Norfolk Quality of Life Diabetic Neuropathy (QoL-DN)), as opposed to only 10% in the placebo control [ 108 ].
MiRNAs hold potential as innovative gene therapies but success is heavily reliant on an efficient delivery vector [ 109 , 110 ]. If indeed miRNAs are to be used in pancreatic cancer, the delivery systems must transport the cargo to the destination site, not evoke an immune response and not have prohibitive production costs so that wide-spread adoption of the these nanotherapies can be realised.
Abbreviations
Breast Cancer A2
Cyclin-dependent Kinase
Diabetes Mellitus
Deoxyribonucleic acid
Eukaryotic Initiation Factor 4E
Extracellular Signal-regulated Kinase
Fine Needle Aspiration
GTPase Activating Protein
Guanosine Triphosphate
Kirsten Rat Sarcoma
Lactate Dehydrogenase
Mitogen-activated Protein Kinase
micro Ribonucleic acid
messenger Ribonucleic acid
Norepinephrine
Ongogenic micro Ribonucleic acid
Pancreatic Intraepithelial Neoplasia
Pancreatic Cancer
Platelet-derived Growth Factor Receptor b
Phosphoinositide-3-kinase
RNA-induced silencing complex
Ribonucleic acid
Mothers Against Decapentaplegic
Chromatin Subfamily C Member 1
Transforming Growth Factor β
Threonic Kinase Receptor II
Untranslated Region
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Afra Z. Daoud and Eoghan J. Mulholland contributed equally to this work.
Acknowledgements
Not Applicable.
Authors’ contributions
HM was the lead PI and refined the manuscript. AD, EM and GC drafted the manuscript. AD and EM produced all the figures. All authors read and approved the final manuscript.
Funding
No funding to declare.
Availability of data and materials
Not Applicable.
Ethics approval and consent to participate
Not Applicable.
Consent for publication
Not Applicable.
Competing interests
The authors declare that they have no competing interests.
References
1. https://www.who.int/en/news-room/fact-sheets/detail/cancer .
2. “Pancreatic cancer statistics | Cancer Research UK.” [Online]. Available: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/pancreatic-cancer . [Accessed: 06-Jan-2017].
3. Costa-Silva B Aiello NM Ocean AJ Singh S Zhang H Thakur BK Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver Nat Cell Biol 2015 17 6 816 826 10.1038/ncb3169 25985394 PMC5769922
4. Paiella S, Sandini M, Gianotti L, Butturini G, Salvia R, Bassi C. The prognostic impact of Para-aortic lymph node metastasis in pancreatic cancer: A systematic review and meta-analysis. Eur J Surg Oncol [Internet] 2016 May;42(5):616–624. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0748798316000974 10.1016/j.ejso.2016.02.003 26916137
5. Li Z, Shang H, Zhang X, Zhang H, Bao J, Hao C. Surgical treatment for locally advanced pancreatic cancer localized in the pancreatic body and tail (report of 11 cases). Int J Clin Exp Med [Internet]. 2015;8(3):4676–4681. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26064401 . PMC4443235 26064401
6. Yachida S Jones S Bozic I Antal T Leary R Fu B Distant metastasis occurs late during the genetic evolution of pancreatic cancer Nature. 2010 467 7319 1114 1117 10.1038/nature09515 20981102 PMC3148940
7. Evans J Chapple A Salisbury H Corrie P Ziebland S ‘It can’t be very important because it comes and goes’-patients’ accounts of intermittent symptoms preceding a pancreatic cancer diagnosis: A qualitative study BMJ Open 2014 4 2 6 8 10.1136/bmjopen-2013-004215 PMC3932002 24549161
8. Muniraj T, Chari ST. Diabetes and pancreatic cancer. Minerva Gastroenterol Dietol [Internet]. 2012 Dec;58(4):331–345. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23207610 . PMC3932318 23207610
9. Wang L Bai Y-Y Yang Y Hu F Wang Y Yu Z Diabetes mellitus stimulates pancreatic cancer growth and epithelial-mesenchymal transition-mediated metastasis via a p38 MAPK pathway Oncotarget. 2016 7 25 38539 38550 27413117 10.18632/oncotarget.9533 PMC5122409
10. Javeed N Sagar G Dutta SK Smyrk TC Lau JS Bhattacharya S Pancreatic cancer-derived exosomes cause paraneoplastic β-cell dysfunction Clin Cancer Res 2015 21 7 1722 1733 10.1158/1078-0432.CCR-14-2022 25355928 PMC4383684
11. De Braud F Cascinu S Gatta G Cancer of pancreas Crit Rev Oncol Hematol. 2004 50 2 147 155 10.1016/S1040-8428(03)00156-2 15157663
12. Jones S, Zhang X, Parsons DW, Lin JC-H, Leary RJ, Angenendt P, et al. Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses. Science (80- ). 2008 Sep;321(5897):1801 LP – 1801806. 10.1126/science.1164368 PMC2848990 18772397
13. Rozenbium E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, et al. Tumor-suppressive Pathways in Pancreatic Carcinoma. Cancer Res. 1997;57(9):1731–4 9135016
14. Mutations K Ductal P Pancreatic Ductal 1994 145 6 1547 1548 PMC1887480 7992857
15. Khan MA Azim S Zubair H Bhardwaj A Patel G Khushman M Molecular drivers of Pancreatic Cancer pathogenesis: looking inward to move forward Int J Mol Sci 2017 18 4 779 10.3390/ijms18040779 PMC5412363 28383487
16. Maitra A H. Hruban R. Pancreatic Cancer Cancer Res 2008 3 1 30
17. Hingorani SR Tuveson DA Ras redux: rethinking how and where Ras acts Curr Opin Genet Dev 2003 13 1 6 13 10.1016/S0959-437X(02)00017-5 12573429
18. Jonckheere N Vasseur R Van Seuningen I The cornerstone K-RAS mutation in pancreatic adenocarcinoma: from cell signaling network, target genes, biological processes to therapeutic targeting Crit Rev Oncol Hematol 2017 111 7 19 10.1016/j.critrevonc.2017.01.002 28259298
19. Collins Meredith A. Bednar Filip Zhang Yaqing Brisset Jean-Christophe Galbán Stefanie Galbán Craig J. Rakshit Sabita Flannagan Karen S. Adsay N. Volkan Pasca di Magliano Marina Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice Journal of Clinical Investigation 2012 122 2 639 653 10.1172/JCI59227 22232209 PMC3266788
20. Ying H Kimmelman AC Lyssiotis CA Hua S Chu GC Fletcher-sananikone E Oncogenic Kras maintains Pancreatic tumors through regulation of anabolic glucose metabolism Cell. 2010 149 3 656 670 10.1016/j.cell.2012.01.058 PMC3472002 22541435
21. Singh Anurag Greninger Patricia Rhodes Daniel Koopman Louise Violette Sheila Bardeesy Nabeel Settleman Jeff A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival Cancer Cell 2009 15 6 489 500 10.1016/j.ccr.2009.03.022 19477428 PMC2743093
22. Bernard Weinstein I Addiction to oncogenes: the Achilles heal of Cancer: DISCOVER: all subjects S CIENCE ’ S COMPASS 2002 297 July 64 65 10.1126/science.1073096 12098689
23. Collins Meredith A. Brisset Jean-Christophe Zhang Yaqing Bednar Filip Pierre Josette Heist Kevin A. Galbán Craig J. Galbán Stefanie di Magliano Marina Pasca Metastatic Pancreatic Cancer Is Dependent on Oncogenic Kras in Mice PLoS ONE 2012 7 12 e49707 10.1371/journal.pone.0049707 23226501 PMC3513322
24. Nan X Tamgüney TM Collisson EA Lin L-J Pitt C Galeas J Ras-GTP dimers activate the mitogen-activated protein kinase (MAPK) pathway Proc Natl Acad Sci 2015 112 26 7996 8001 10.1073/pnas.1509123112 26080442 PMC4491781
25. Roy Sanjit K Srivastava Rakesh K Shankar Sharmila Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer Journal of Molecular Signaling 2010 5 10 10.1186/1750-2187-5-10 20642839 PMC2915986
26. Boucher MJ Morisset J Vachon PH Reed JC Lainé J Rivard N MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-XL, and Mcl-1 and promotes survival of human pancreatic cancer cells J Cell Biochem 2000 79 3 355 369 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0 10972974
27. Taniuchi K Furihata M Hanazaki K Iwasaki S Tanaka K Shimizu T Peroxiredoxin 1 promotes pancreatic cancer cell invasion by modulating p38 MAPK activity Pancreas. 2015 44 2 331 340 10.1097/MPA.0000000000000270 25426613 PMC4327392
28. Handra-Luca Adriana Lesty Claude Hammel Pascal Sauvanet Alain Rebours Vinciane Martin Antoine Fagard Remi Fléjou Jean-François Faivre Sandrine Bédossa Pierre Ruszniewski Philippe Couvelard Anne Biological and Prognostic Relevance of Mitogen-Activated Protein Kinases in Pancreatic Adenocarcinoma Pancreas 2012 41 3 416 421 10.1097/MPA.0b013e318238379d 22158075
29. Zhong Y Naito Y Cope L Naranjo-Suarez S Saunders T Hong SM Functional p38 MAPK identified by biomarker profiling of pancreatic cancer restrains growth through JNK inhibition and correlates with improved survival Clin Cancer Res 2014 20 23 6200 6211 10.1158/1078-0432.CCR-13-2823 24963048 PMC4866510
30. Huang X Wang H Yuan Z Huang J Zheng Q Norepinephrine stimulates pancreatic cancer cell proliferation, migration and invasion via beta-adrenergic receptor-dependent activation of P38/MAPK pathway Hepatogastroenterology. 2012 59 115 889 893 22020907 10.5754/hge11476
31. Ding XZ Adrian TE MEK/ERK-mediated proliferation is negatively regulated by p38 MAP kinase in the human pancreatic cancer cell line, PANC-1 Biochem Biophys Res Commun 2001 282 2 447 453 10.1006/bbrc.2001.4595 11401480
32. Cuadrado A Nebreda AR Mechanisms and functions of p38 MAPK signalling Biochem J 2010 429 3 403 417 10.1042/BJ20100323 20626350
33. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, et al. Abrogation of the Rb/p16 Tumor-suppressive Pathway in Virtually All Pancreatic Carcinomas. Cancer Res. 1997;57(15):3126–30. 9242437
34. Ouelle DE Zindy F Ashmun RA Sherr CJ Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest Cell. 1995 83 6 993 1000 10.1016/0092-8674(95)90214-7 8521522
35. Bertoli C Skotheim JM De Bruin RAM Street G de Bruin RAM Control of cell cycle transcription during G1 and S phases Nat Rev Mol Cell Biol 2015 14 8 518 528 10.1038/nrm3629 PMC4569015 23877564
36. Vogelstein B Lane D Levine AJ Surfing the p53 network Nature. 2000 408 6810 307 310 10.1038/35042675 11099028
37. Makohon-Moore A Iacobuzio-Donahue CA Pancreatic cancer biology and genetics from an evolutionary perspective Nat Rev Cancer 2016 16 9 553 565 10.1038/nrc.2016.66 27444064 PMC5739515
38. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, et al. p53 Mutations in Pancreatic Carcinoma and Evidence of Common Involvement of Homocopolymer Tracts in DNA Microdeletions. Cancer Res. 1994;54(11):3025–33. 8187092
39. Marcel V Catez F Diaz JJ P53, a translational regulator: contribution to its tumour-suppressor activity Oncogene. 2015 34 44 5513 5523 10.1038/onc.2015.25 25728674
40. Herman JM, Crane CH, Iacobuzio-Donahue C, Abrams RA. Pancreatic Cancer. In: Clinical Radiation Oncology [Internet]. Elsevier; 2016. p. 934–959.e6. Available from: https://linkinghub.elsevier.com/retrieve/pii/B9780323240987000484
41. Siegel PM Massagué J Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer Nat Rev Cancer 2003 3 11 807 820 10.1038/nrc1208 14557817
42. Macias Maria J. Martin-Malpartida Pau Massagué Joan Structural determinants of Smad function in TGF-β signaling Trends in Biochemical Sciences 2015 40 6 296 308 10.1016/j.tibs.2015.03.012 25935112 PMC4485443
43. Budi EH Duan D Derynck R Transforming growth factor- b receptors and Smads : regulatory complexity and functional versatility Trends Cell Biol 2017 27 9 658 672 10.1016/j.tcb.2017.04.005 28552280
44. Oshima Minoru Okano Keiichi Muraki Shinobu Haba Reiji Maeba Takashi Suzuki Yasuyuki Yachida Shinichi Immunohistochemically Detected Expression of 3 Major Genes (CDKN2A/p16, TP53, and SMAD4/DPC4) Strongly Predicts Survival in Patients With Resectable Pancreatic Cancer Annals of Surgery 2013 258 2 336 346 10.1097/SLA.0b013e3182827a65 23470568
45. Schmiedel Jörn M. Klemm Sandy L. Zheng Yannan Sahay Apratim Blüthgen Nils Marks Debora S. van Oudenaarden Alexander MicroRNA control of protein expression noise Science 2015 348 6230 128 132 10.1126/science.aaa1738 25838385
46. Mulholland EJ, Dunne N, McCarthy HO. MicroRNA as Therapeutic Targets for Chronic Wound Healing. Mol Ther - Nucleic Acids [Internet]. 2017 Sep 15 [cited 2018 Jan 29];8:46–55. Available from: https://www.sciencedirect.com/science/article/pii/S2162253117301865?via%3Dihub 10.1016/j.omtn.2017.06.003 PMC5485763 28918046
47. Saini HK Griffiths-jones S Enright AJ Genomic analysis of human microRNA transcripts 2007 104 45 1 6 10.1073/pnas.0703890104 PMC2077053 17965236
48. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? 2008;9(february). 10.1038/nrg2290 18197166
49. Hill Christopher G. Jabbari Neda Matyunina Lilya V. McDonald John F. Functional and Evolutionary Significance of Human MicroRNA Seed Region Mutations PLoS ONE 2014 9 12 e115241 10.1371/journal.pone.0115241 25501359 PMC4264867
50. Dueck A. Ziegler C. Eichner A. Berezikov E. Meister G. microRNAs associated with the different human Argonaute proteins Nucleic Acids Research 2012 40 19 9850 9862 10.1093/nar/gks705 22844086 PMC3479175
51. Ambros V Chen X The regulation of genes and genomes by small RNAs Development. 2007 134 9 1635 1641 10.1242/dev.002006 17409118
52. Meister G Landthaler M Patkaniowska A Dorsett Y Teng G Tuschl T Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs Mol Cell 2004 15 2 185 197 10.1016/j.molcel.2004.07.007 15260970
53. Zhang Jian Li Sha Li Lu Li Meng Guo Chongye Yao Jun Mi Shuangli Exosome and Exosomal MicroRNA: Trafficking, Sorting, and Function Genomics, Proteomics & Bioinformatics 2015 13 1 17 24 10.1016/j.gpb.2015.02.001 PMC4411500 25724326
54. Wang Xiaofeng Luo Guangtao Zhang Kundong Cao Jun Huang Chen Jiang Tao Liu Bingya Su Liping Qiu Zhengjun Hypoxic Tumor-Derived Exosomal miR-301a Mediates M2 Macrophage Polarization via PTEN/PI3Kγ to Promote Pancreatic Cancer Metastasis Cancer Research 2018 78 16 4586 4598 10.1158/0008-5472.CAN-17-3841 29880482
55. Pang Wenjing Su Jiaojiao Wang Yalei Feng Hui Dai Xin Yuan Yaozong Chen Xi Yao Weiyan Pancreatic cancer-secreted miR-155 implicates in the conversion from normal fibroblasts to cancer-associated fibroblasts Cancer Science 2015 106 10 1362 1369 10.1111/cas.12747 26195069 PMC4638007
56. Wang M, Yu F, Ding H, Wang Y, Li P, Wang K. Emerging Function and Clinical Values of Exosomal MicroRNAs in Cancer. Mol Ther - Nucleic Acids [Internet]. 2019 Jun;16:791–804. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2162253119301209 10.1016/j.omtn.2019.04.027 PMC6545365 31163321
57. Zhang Baohong Pan Xiaoping Cobb George P. Anderson Todd A. microRNAs as oncogenes and tumor suppressors Developmental Biology 2007 302 1 1 12 10.1016/j.ydbio.2006.08.028 16989803
58. Iorio Marilena V. Croce Carlo M. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review EMBO Molecular Medicine 2012 4 3 143 159 10.1002/emmm.201100209 22351564 PMC3376845
59. Lu J Getz G Miska EA Varez-Saavedra E Lamb J Peck D MicroRNA expression profiles classify human cancers Nature. 2005 435 7043 834 838 10.1038/nature03702 15944708
60. Szafranska A E Davison T S John J Cannon T Sipos B Maghnouj A Labourier E Hahn S A MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma Oncogene 2007 26 30 4442 4452 10.1038/sj.onc.1210228 17237814
61. Moody L He H Pan Y-X Chen H Methods and novel technology for microRNA quantification in colorectal cancer screening Clin Epigenetics 2017 9 1 119 10.1186/s13148-017-0420-9 29090038 PMC5655825
62. Yonemori K, Seki N, Idichi T, Kurahara H, Osako Y, Koshizuka K, et al. The microRNA expression signature of pancreatic ductal adenocarcinoma by RNA sequencing: anti-tumour functions of the microRNA-216 cluster. Oncotarget [Internet]. 2017 Sep 19;8(41):70097–70115. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29050264 . 10.18632/oncotarget.19591 PMC5642539 29050264
63. Mitchell PS Parkin RK Kroh EM Fritz BR Wyman SK Pogosova-Agadjanyan EL Circulating microRNAs as stable blood-based markers for cancer detection Proc Natl Acad Sci U S A 2008 105 30 10513 10518 10.1073/pnas.0804549105 18663219 PMC2492472
64. Wang H, Peng R, Wang J, Qin Z, Xue L. Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage. Clin epigenetics [Internet]. 2018;10:59. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29713393 . 10.1186/s13148-018-0492-1 PMC5913875 29713393
65. Rawlings-Goss RA, Campbell MC, Tishkoff SA. Global population-specific variation in miRNA associated with cancer risk and clinical biomarkers. BMC Med Genomics [Internet]. 2014 Aug 28;7:53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25169894 . 10.1186/1755-8794-7-53 PMC4159108 25169894
66. Crnogorac-Jurcevic T Efthimiou E Capelli P Blaveri E Baron a, Terris B, et al. gene expression profiles of pancreatic cancer and stromal desmoplasia Oncogene 2001 20 50 7437 7446 10.1038/sj.onc.1204935 11704875
67. Humeau M Torrisani J Cordelier P MiRNA in clinical practice: Pancreatic cancer Clin Biochem 2013 46 10–11 933 936 10.1016/j.clinbiochem.2013.03.019 23570860
68. Słotwiński Robert Lech Gustaw Słotwińska Sylwia Małgorzata MicroRNAs in pancreatic cancer diagnosis and therapy Central European Journal of Immunology 2018 43 3 314 324 10.5114/ceji.2018.80051 30588176 PMC6305615
69. ABUE MAKOTO YOKOYAMA MISA SHIBUYA RIE TAMAI KEIICHI YAMAGUCHI KAZUNORI SATO IKURO TANAKA NOBUYUKI HAMADA SHIN SHIMOSEGAWA TOORU SUGAMURA KAZUO SATOH KENNICHI Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer International Journal of Oncology 2014 46 2 539 547 10.3892/ijo.2014.2743 25384963 PMC4277249
70. Wray CJ Ahmad SA Matthews JB Lowy AM Surgery for pancreatic cancer: recent controversies and current practice Gastroenterology 2005 128 6 1626 1641 10.1053/j.gastro.2005.03.035 15887155
71. Hong TH Park IY Tanaka K Inoue Y Kusunoki M Boland C MicroRNA expression profiling of diagnostic needle aspirates from surgical pancreatic cancer specimens Ann Surg Treat Res. 2014 87 6 290 10.4174/astr.2014.87.6.290 25485236 PMC4255547
72. Ballehaninna Umashankar K. Chamberlain Ronald S. Serum CA 19-9 as a Biomarker for Pancreatic Cancer—A Comprehensive Review Indian Journal of Surgical Oncology 2011 2 2 88 100 10.1007/s13193-011-0042-1 22693400 PMC3244191
73. Winter JM Yeo CJ Brody JR Diagnostic , Prognostic , and Predictive Biomarkers in Pancreatic Cancer 2012 2013 15 22 10.1002/jso.23192 22729569
74. Saito Yoshimasa Jones Peter M. Epigenetic Activation of Tumor Suppressor MicroRNAs in Human Cancer Cells Cell Cycle 2006 5 19 2220 2222 10.4161/cc.5.19.3340 17012846
75. Li Y Sarkar FH MicroRNA targeted therapeutic approach for pancreatic cancer Int J Biol Sci 2016 12 3 326 337 10.7150/ijbs.15017 26929739 PMC4753161
76. Eun JL Gusev Y Jiang J Nuovo GJ Lerner MR Frankel WL Expression profiling identifies microRNA signature in pancreatic cancer Int J Cancer 2007 120 5 1046 1054 17149698 10.1002/ijc.22394 PMC2680248
77. Habbe N Koorstra JBM Mendell JT Offerhaus GJ Ji KR Feldmann G MicroRNA miR-155 is a biomarker of early pancreatic neoplasia Cancer Biol Ther 2009 8 4 340 346 10.4161/cbt.8.4.7338 19106647 PMC2692997
78. Hong TH Park IY MicroRNA expression profiling of diagnostic needle aspirates from surgical pancreatic cancer specimens Ann Surg Treat Res 2014 87 6 290 297 10.4174/astr.2014.87.6.290 25485236 PMC4255547
79. Zhang Y Li M Wang H Fisher WE Lin PH Yao Q Profiling of 95 MicroRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis World J Surg 2009 33 4 698 709 10.1007/s00268-008-9833-0 19030927 PMC2933040
80. Mees ST Schleicher C Mardin WA Senninger N Colombo-Benkmann M Haier J Analyzing miRNAs in ductal adenocarcinomas of the pancreas J Surg Res 2011 169 2 241 246 10.1016/j.jss.2009.10.005 20080250
81. du Rieu MC, Torrisani J, Selves J, Al Saati T, Souque A, Dufresne M, et al. MicroRNA-21 Is Induced Early in Pancreatic Ductal Adenocarcinoma Precursor Lesions. Clin Chem. 2010;56:603–12. 10.1373/clinchem.2009.137364 20093556
82. Nakata K Ohuchida K Mizumoto K Kayashima T Ikenaga N Sakai H MicroRNA-10b is overexpressed in pancreatic cancer, promotes its invasiveness, and correlates with a poor prognosis Surgery. 2011 150 5 916 922 10.1016/j.surg.2011.06.017 22018284
83. Namkung J Kwon W Choi Y Yi SG Han S Kang MJ Molecular subtypes of pancreatic cancer based on miRNA expression profiles have independent prognostic value J Gastroenterol Hepatol 2015 31 n/a-n/a 10.1111/jgh.13253 26644397
84. Wu P, Taubert H. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer. 2009. 10.1002/ijc.24687 19551852
85. Giovannetti Elisa Funel Niccola Peters Godefridus J. Del Chiaro Marco Erozenci Leyla A. Vasile Enrico Leon Leticia G. Pollina Luca E. Groen Annemieke Falcone Alfredo Danesi Romano Campani Daniela Verheul Henk M. Boggi Ugo MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity Cancer Research 2010 70 11 4528 4538 10.1158/0008-5472.CAN-09-4467 20460539
86. Asangani I A Rasheed S A K Nikolova D A Leupold J H Colburn N H Post S Allgayer H MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer Oncogene 2007 27 15 2128 2136 10.1038/sj.onc.1210856 17968323
87. Guo S, Fesler A, Wang H, Ju J. microRNA based prognostic biomarkers in pancreatic Cancer. Biomark Res [Internet]. 2018;6(1):18. Available from: https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-018-0131-1 10.1186/s40364-018-0131-1 PMC5963153 29942514
88. Bloomston M Frankel WL Petrocca F Volinia S Alder H Hagan JP MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis Jama. 2007 297 17 1901 1908 10.1001/jama.297.17.1901 17473300
89. Iwagami Y Eguchi H Nagano H Akita H Hama N Wada H miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1 Br J Cancer 2013 109 2 502 511 10.1038/bjc.2013.320 23799850 PMC3721395
90. Yu Jun Ohuchida Kenoki Mizumoto Kazuhiro Sato Norihiro Kayashima Tadashi Fujita Hayato Nakata Kouhei Tanaka Masao MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation Molecular Cancer 2010 9 1 169 10.1186/1476-4598-9-169 20579395 PMC2909980
91. Li Y VandenBoom TG Kong D Wang Z Ali S Philip PA Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells Cancer Res 2009 69 16 6704 6712 10.1158/0008-5472.CAN-09-1298 19654291 PMC2727571
92. Liang C Wang Z Li YY Yu BH Zhang F Li HY miR-33a suppresses the nuclear translocation of β-catenin to enhance gemcitabine sensitivity in human pancreatic cancer cells Tumor Biol 2015 36 12 9395 9403 10.1007/s13277-015-3679-5 26113407
93. Chaudhary AK Mondal G Kumar V Kattel K Mahato RI Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205 Cancer Lett 2017 402 Supplement C 1 8 10.1016/j.canlet.2017.05.007 28536008 PMC5673079
94. Ouyang H Gore J Deitz S Korc M microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-β actions Oncogene 2013 33 38 4664 4674 10.1038/onc.2013.405 24096486 PMC3979498
95. Preis M Gardner TB Gordon SR Pipas JM Mackenzie TA Klein EE MicroRNA-10b expression correlates with response to Neoadjuvant therapy and survival in Pancreatic Ductal adenocarcinoma Clin Cancer Res 2011 17 17 5812 5821 10.1158/1078-0432.CCR-11-0695 21652542 PMC3167031
96. Iliopoulos Dimitrios Drakaki Alexandra MicroRNA-gene signaling pathways in pancreatic cancer Biomedical Journal 2013 36 5 200 10.4103/2319-4170.119690 24225187
97. Kong Yi W Ferland-McCollough David Jackson Thomas J Bushell Martin microRNAs in cancer management The Lancet Oncology 2012 13 6 e249 e258 10.1016/S1470-2045(12)70073-6 22652233
98. Ohuchida K Mizumoto K Kayashima T Fujita H Moriyama T Ohtsuka T MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of Pancreatic Cancer Ann Surg Oncol 2011 18 8 2381 2387 10.1245/s10434-011-1602-x 21347785 PMC3136688
99. Khan MA, Zubair H, Srivastava SK, Singh S, Singh AP. Insights into the role of microRNAs in Pancreatic Cancer pathogenesis: potential for diagnosis, prognosis, and therapy. Adv Exp Med biol [Internet]. 2015;889:71–87. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26658997 . 10.1007/978-3-319-23730-5_5 PMC5706654 26658997
100. Mikamori M, Yamada D, Eguchi H, Hasegawa S, Kishimoto T, Tomimaru Y, et al. MicroRNA-155 controls exosome synthesis and promotes gemcitabine resistance in Pancreatic Ductal adenocarcinoma. Sci rep [Internet]. 2017;7:42339. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28198398 . 10.1038/srep42339 PMC5309735 28198398
101. Schultz NA Andersen KK Roslind A Willenbrock H Wøjdemann M Johansen JS Prognostic MicroRNAs in Cancer tissue from patients operated for Pancreatic Cancer—five MicroRNAs in a prognostic index World J Surg 2012 36 11 2699 2707 10.1007/s00268-012-1705-y 22851141
102. Pai Priya Rachagani Satyanarayana Are Chandrakanth Batra Surinder Prospects of miRNA-Based Therapy for Pancreatic Cancer Current Drug Targets 2013 14 10 1101 1109 10.2174/13894501113149990181 23834151 PMC3924540
103. Paik Woo Hyun Song Byeong Jun Kim Hyoung Woo Kim Hye Ree Hwang Jin-Hyeok MicroRNA-200c as a Prognostic Biomarker for Pancreatic Cancer The Korean Journal of Gastroenterology 2015 66 4 215 10.4166/kjg.2015.66.4.215 26493507
104. Liu Y-A, Zhang Y, Zheng Z, Li K, Wu X-H, Du Q-G, et al. MicroRNA-216b reduces growth, migration and invasion of pancreatic ductal adenocarcinoma cells by directly targeting ρ-associated coiled-coil containing protein kinase 1. Oncol Lett [Internet]. 2018;15(5):6745–51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29616134 . 10.3892/ol.2018.8109 PMC5876443 29616134
105. Yi Juanjuan Li Shubin Wang Chao Cao Nana Qu Hang Cheng Cuilin Wang Zhenyu Wang Lu Zhou Liping Potential applications of polyphenols on main ncRNAs regulations as novel therapeutic strategy for cancer Biomedicine & Pharmacotherapy 2019 113 108703 10.1016/j.biopha.2019.108703 30870719
106. https://clinicaltrials.gov/ct2/show/NCT03432624 .
107. Beg MS, Brenner A, Sachdev J, Ejadi S, Borad M, Kang Y-K, et al. Abstract C43: Safety, tolerability, and clinical activity of MRX34, the first-in-class liposomal miR-34 mimic, in patients with advanced solid tumors. Mol Cancer Ther [Internet]. 2015;14(12 Supplement 2):C43–C43. Available from: http://mct.aacrjournals.org/lookup/doi/10.1158/1535-7163.TARG-15-C43
108. https://www.drugdevelopment-technology.com/projects/onpattro-for-hereditary-transthyretin-mediated-amyloidosis/ .
109. Cole G, Ali AA, McErlean E, Mulholland EJ, Short A, McCrudden CM, et al. DNA vaccination via RALA nanoparticles in a microneedle delivery system induces a potent immune response against the endogenous prostate cancer stem cell antigen. Acta Biomater [Internet]. 2019 Jul; Available from: https://linkinghub.elsevier.com/retrieve/pii/S1742706119304830 10.1016/j.actbio.2019.07.003 31299353
110. McCarthy Helen O. McCaffrey Joanne McCrudden Cian M. Zholobenko Aleksey Ali Ahlam A. McBride John W. Massey Ashley S. Pentlavalli Sreekanth Chen Kun-Hung Cole Grace Loughran Stephen P. Dunne Nicholas J. Donnelly Ryan F. Kett Victoria L. Robson Tracy Development and characterization of self-assembling nanoparticles using a bio-inspired amphipathic peptide for gene delivery Journal of Controlled Release 2014 189 141 149 10.1016/j.jconrel.2014.06.048 24995949